PHARMACODYNAMICS OF ESOMEPRAZOLE ASSESSED USING PH/IMPEDANCE MONITORING IN NEONATAL PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

(1) Sheffield Children?s Hospital, Sheffield, United Kingdom

(2) Women?s and Children?sHospital, North Adelaide, Australia

(3) Universitaetsklinikum Aachen, Aachen, Germany

(4) AstraZeneca LP, Wilmington, United States

(5) AstraZeneca R&D, Mölndal, Sweden



This item was part of the Oesophageal, Gastric and Duodenal Disorders II session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A231